Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B.
In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials.
Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial.
Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 4, 25 | -1.39 Decreased by -12.10% | -0.72 Decreased by -92.15% |
| Nov 27, 24 | -1.37 Decreased by -34.31% | -0.92 Decreased by -48.59% |
| Aug 8, 24 | -1.38 Decreased by -43.75% | -0.55 Decreased by -150.91% |
| May 9, 24 | -1.02 Decreased by -326.67% | -0.16 Decreased by -537.50% |
| Feb 6, 24 | -1.24 Decreased by -217.95% | -0.82 Decreased by -51.22% |
| Nov 29, 23 | -1.02 Decreased by -25.93% | -0.60 Decreased by -70.00% |
| Aug 7, 23 | -0.96 Decreased by -41.18% | -0.65 Decreased by -47.69% |
| May 2, 23 | 0.45 Increased by +9.76% | -0.64 Increased by +170.31% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 2.50 M Decreased by -29.60% | -173.09 M Decreased by -30.27% | Decreased by -6.92 K% Decreased by -85.04% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -170.54 M Decreased by -55.49% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -170.79 M Decreased by -65.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -125.30 M Decreased by -357.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 3.55 M Decreased by -94.32% | -132.86 M Decreased by -217.77% | Decreased by -3.74 K% Decreased by -5.50 K% |
| Sep 30, 23 | 16.10 M Decreased by -49.02% | -109.68 M Decreased by -27.62% | Decreased by -681.36% Decreased by -150.33% |
| Jun 30, 23 | 15.82 M Decreased by -51.18% | -102.95 M Decreased by -44.62% | Decreased by -650.53% Decreased by -196.21% |
| Mar 31, 23 | 146.27 M Decreased by -3.65% | 48.67 M Increased by +9.71% | Increased by +33.28% Increased by +13.87% |